bioMérieux S.A. (LON:0RUG)

Market Cap	10.98B
Revenue (ttm)	3.23B
Net Income (ttm)	348.71M
Shares Out	n/a
EPS (ttm)	2.94
PE Ratio	31.48
Forward PE	n/a
Dividend	0.72 (0.63%)
Ex-Dividend Date	Jun 7, 2024

Volume	49,705
Average Volume	38,732
Open	114.35
Previous Close	113.73
Day's Range	112.40 - 114.80
52-Week Range	72.93 - 92.27
Beta	0.27
RSI	51.96
Earnings Date	Mar 14, 2025

About bioMérieux

bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; V...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1963
• Employees: 13,982
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RUG

Financial Performance

In 2023, bioMérieux's revenue was 3.67 billion, an increase of 2.38% compared to the previous year's 3.59 billion. Earnings were 357.60 million, a decrease of -20.95%.

Financial numbers in EUR